Critical Challenges and Emerging Controversies in Managing Patients with Myelodysplastic Syndrome (MDS): The Role of Risk, Age, and Transplantation in Determining Optimal Therapy for MDS
Frederick R. Appelbaum, MD

Myelodysplastic Syndrome (MDS): FAB and WHO Classification Systems for MDS and Their Implications for Clinical Management: Applying Risk Stratification, Age, and Other Disease Profile Factors to Patient Care
Jaroslaw Maciejewski, MD, PhD

The Role of Hypomethylating Agents Across the Disease Spectrum for MDS: Mechanisms, Approach in the Elderly, and Emerging Data About Timing of Bone Transplantation What do the Clinical Trials Teach Us About Optimal Approaches to High-Risk Patients?
Frederick R. Appelbaum, MD

Timing and Triggers for Allogeneic Bone Transplantation—Identifying Critical Triggers for Improving Long-Term Survival in MDS
Richard M. Stone, MD

The Evolving Role of Combination Therapy in MDS: Cytotoxic Drugs, Hypomethylating, and Immune Modulating Agents: Why? In Whom? When? In What Combination?
Guillermo Garcia-Manero, MD

International Experts’ Panel Discussion and Q&A
Faculty Panel